Medication taper and withdrawal monitoring

The manuals converge on the need for active monitoring during medication tapering or discontinuation before dosing. Across the extracts, taper periods are treated as clinically sensitive, with repeated checks for withdrawal symptoms, worsening mood or depression, and suicidality. Several manuals also emphasise frequent contact, documentation of medication changes, and readiness to escalate care if deterioration emerges. They also overlap in using structured monitoring during the taper phase. One trial specifies weekly DESS ratings, another uses the C-SSRS at each contact or visit, and others describe weekly clinic safety visits or frequent contact to track withdrawal and symptom worsening. The alcohol and opioid studies extend this same logic to withdrawal monitoring around dosing or treatment, using CIWA-Ar or SOWS-type measures and reassessing symptoms before and after treatment. The main differences are in how prescriptive and how medically specific the monitoring is. Some manuals set explicit taper durations and washout periods, such as at least 2 weeks, or 5 weeks for fluoxetine, while others leave taper rate to clinician discretion or participant choice. The alcohol protocol focuses on withdrawal thresholds and detoxification before proceeding, the opioid study focuses on acute withdrawal response, and the depression protocols place more emphasis on antidepressant tapering, symptom deterioration, and suicidality during the pre-dose period.